Vimarsana
Biggest News Aggregation in the World

Page 12 - Accessed March News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Accessed March. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Accessed March Today - Breaking & Trending Today

Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP) - Vimarsana News

Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

CTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening Acute Events and Debilitating Chronic Symptoms ADZYNMA is the First and Only Recombinant ADAMTS13 Enzyme...

Best CD rates today: Don't wait on APYs of 5.3% and up across all terms — March 26, 2024 - Vimarsana News

Best CD rates today: Don't wait on APYs of 5.3% and up across all terms — March 26, 2024

Plan ahead with today's best rates in 23 years on certificates of deposits for a range of CD terms — from 6 months to 5 years.

Source: aol.com
Phase 3 Trial of AXS-12 for Narcolepsy Meets Primary Endpoint - Vimarsana News

Phase 3 Trial of AXS-12 for Narcolepsy Meets Primary Endpoint

The treatment significantly reduced the frequency of cataplexy attacks in patients with narcolepsy compared with placebo.

AstraZeneca : Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) - Form 6-K -March 25, 2024 at 07:31 am EDT - Vimarsana News

AstraZeneca : Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) - Form 6-K -March 25, 2024 at 07:31 am EDT

A0626i FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or...

Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635 - Vimarsana News

Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635

VRG50635 is one of the first drugs to enter clinical trials that was entirely discovered and developed using an AI-enabled platformSOUTH SAN FRANCISCO, Calif. and BARCELONA, Spain, March 25, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a leading clinical-stage biotechnology company, and Ferrer, an international B Corp pharmaceutical company with an increasing focus in rare neurological disorders, have announced a strategic collaboration to co-develop VRG50635, Verge’s lead drug candidate, for the tr

Source: yahoo.com